Approval

Anbirui Companion Diagnostic Approved

China's NMPA approved a companion diagnostic kit for Anbirui to detect EGFR exon 20 insertions in patients with non-small cell lung cancer. Anbirui received conditional NMPA drug approval in April 2026 for eligible adults previously treated with or intolerant to platinum-based chemotherapy. Anbirui was added to China's 2026 national reimbursement drug list, which takes effect on January 1, 2027.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call